Home/Filings/4/0001209191-23-054022
4//SEC Filing

SMITH WAYNE T 4

Accession 0001209191-23-054022

CIK 0001108109other

Filed

Oct 31, 8:00 PM ET

Accepted

Nov 1, 4:17 PM ET

Size

20.8 KB

Accession

0001209191-23-054022

Insider Transaction Report

Form 4
Period: 2023-10-31
SMITH WAYNE T
DirectorChairman, President & CEO
Transactions
  • Purchase

    Common Stock

    2023-10-31$2.11/sh+1,000,000$2,110,0005,107,901 total
Holdings
  • Common Stock

    (indirect: By LLC)
    481,721
  • Performance Based Restricted

    Exercise: $0.00Common Stock (180,000 underlying)
    180,000
  • Stock Options (Right to Buy)

    Exercise: $8.81From: 2022-03-01Exp: 2031-02-28Common Stock (90,000 underlying)
    90,000
  • Common Stock

    (indirect: By Trust)
    1,606,842
  • Restricted Stock Units

    Exercise: $0.00Common Stock (29,268 underlying)
    29,268
  • Stock Options (Right to Buy)

    Exercise: $4.99From: 2020-03-01Exp: 2029-02-28Common Stock (78,750 underlying)
    78,750
  • Stock Options (Right to Buy)

    Exercise: $10.18From: 2023-03-01Exp: 2032-02-29Common Stock (90,000 underlying)
    90,000
  • Restricted Stock Units

    Exercise: $0.00Common Stock (43,089 underlying)
    43,089
  • Stock Options (Right to Buy)

    Exercise: $4.93From: 2021-03-01Exp: 2030-02-28Common Stock (112,500 underlying)
    112,500
  • Stock Units (SU)

    Exercise: $0.00Common Stock (25,225.914 underlying)
    25,225.914
  • Performance Based Restricted

    Exercise: $0.00Common Stock (180,000 underlying)
    180,000
Footnotes (7)
  • [F1]The price reported in Column 4 is a weighted average price of $2.11 per share. These shares were purchased in multiple transactions on 10/31/2023 at prices ranging from $2.03 to $2.14, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F2]The Stock Units were accrued under the Company's Directors' Fees Deferral Plan in lieu of a portion of the Reporting Person's Director Fees and are settled 100% in the Company's common stock on the last business day of the calendar quarter following cessation as a director or upon a date specified by the Reporting Person.
  • [F3]The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2021 and 12/31/2023 (the "2021-2023 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2021-2023 Performance Period.
  • [F4]The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2022 and 12/31/2024 (the "2022-2024 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2022-2024 Performance Period.
  • [F5]The restricted stock units vest in 1/3 increments on the first, second and third anniversary of the date of grant. Based on the Reporting Person's prior deferral election pursuant to the terms of the award agreement, the Reporting Person will be issued that number of shares of common stock of the Company upon the Reporting Person's cessation as a director or upon a date specified by the Reporting Person.
  • [F6]The restricted stock units, which were granted as payment of the Reporting Person's additional annual stipend for serving as the Chair of the Board, vest in 1/3 increments on the first, second and third anniversary of the date of grant. Based on the Reporting Person's prior deferral election pursuant to the terms of the award agreement, the Reporting Person will be issued that number of shares of common stock of the Company upon the Reporting Person's cessation as a director or upon a date specified by the Reporting Person.
  • [F7]Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant.

Issuer

COMMUNITY HEALTH SYSTEMS INC

CIK 0001108109

Entity typeother

Related Parties

1
  • filerCIK 0001018660

Filing Metadata

Form type
4
Filed
Oct 31, 8:00 PM ET
Accepted
Nov 1, 4:17 PM ET
Size
20.8 KB